Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
Founders: Paul Dreier, Fred Regnier, Tim Woenker, Ed Woenker, Jiri Adamec
Established: 2021
Top executives:
- Paul Dreier, CEO
- Fred Regnier, chief technology officer
Equity raised: $6.2 million in two rounds
2024 revenue: about $200,000
Projected 2025 revenue: $4.2 million
Employees: 12
Location: West Lafayette
Affiliations: Elevate Ventures portfolio company, Purdue Research Foundation, Purdue Ventures portfolio company, zWorks nonprofit incubator in Zionsville
Patents: Novilytic said it has a suite of patents and patents pending. The company also has licensed two patents from the Purdue Research Foundation.
What does the company do? Novilytic describes itself as a “bio tools company that helps pharmaceutical scientists and engineers bring better medicines to market much faster and less expensively.” Its Proteometer-L product, launched in early 2023, performs analyses of medicinal antibody batches roughly every 10 minutes instead of the traditional manner, which can take several hours.
What problem is it trying to solve? So many things can go wrong in drug development and production—at many steps in the process. Novilytic’s goal is to be the “canary in the coal mine” for drugmakers with tools designed to give real-time alerts to pharmaceutical companies if a batch of drugs under development is contaminated.
Latest news: Novilytic in March released its Proteometer-CV Kit, which is designed for scientists who are focused on developing monoclonal antibodies, bispecific antibodies or fusion proteins with a human Fc region. In January, Novilytic announced an exclusive distribution partnership with Avantor, a global supplier that will make its products available to laboratories across the United States, European Union and United Kingdom.
Why Novilytic made the list: The company is projecting to reach $48 million in revenue within five years. During that time, the company plans expansions into animal pharmaceutical markets (in 2026), fundamental biopharmaceuticals (in 2027), food proteins and other medical-related products. Also, Novilytic reports that “all of our scientists, engineers and marketing professionals came from Indiana-based universities.”•
Please enable JavaScript to view this content.